Artículos de revistas
Allogeneic Hematopoietic Stem Cell Transplant For Multiple Myeloma [o Transplante Alogênico De Células-tronco Hematopoé Ticas No Tratamento Do Mieloma Múltiplo]
Registro en:
Revista Brasileira De Hematologia E Hemoterapia. , v. 29, n. 1, p. 42 - 47, 2007.
15168484
10.1590/S1516-84842007000100010
2-s2.0-37349018034
Autor
Vigorito A.C.
Aranha F.J.P.
Souza C.A.
Institución
Resumen
Multiple myeloma (MM) is a incurable hematological malignancy with an average survival of 3 years with conventional therapy. Allogeneic hematopoietic cell transplantation (allo - HCT) may cure some patients, but has been associated with a high transplantation-related-mortality (TRM) of over 40%. The potential advantages of allo - HCT are the ability to collect myeloma free stem cells and the graft - versus - myeloma effect. But, despite these factors, long term cure is rare. Relapse continues at a rate of approximately 7% per year with long term follow-up. The graft-versus-host disease (GVHD) can also be a problem, requiring therapy and impairing quality of life. Approaches to improve the outcome of allo - HCT for MM include consideration of patient status, efficacy and toxicity of induction therapy, source of hematopoietic graft, and conditioning regimens. Recent attempts to improve outcome include autologous hematopoietic cell transplantation (AHCT) followed by non - myeloablative allogeneic transplantation, and allo-HCT with T depletion and subsequent donor lymphocyte infusions. With the use of strategies directed at cell signaling, patients' lives can be prolonged, and the quality of their lives can be improved compared with the current approach that transplantation provides, despite its survival benefit. 29 1 42 47 Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant 2006;37:1.069-85Bjorkstrand, B., European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma (2001) Semin Hematol, 38, pp. 219-225 Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1.312-22Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996;88:2.787-93Mehta, J., Tricot, G., Jagannath, S., Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? (1998) Bone Marrow Transplant, 21, pp. 887-892 Gahrton, G., Svensson, H., Cavo, M., Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres (2001) Br J Haematol, 113, pp. 209-216 Catley, L., Anderson, K., Strategies to improve the outcome of stem cell transplantation in multiple myeloma (2004) Hematol J, 5, pp. 9-23 Bird, J.M., Russell, N.H., Samson, D., Minimal residual disease after bone marrow transplantation for multiple myeloma: Evidence for cure in long-term survivors (1993) Bone Marrow Transplant, 12, pp. 651-654 Corradini, P., Voena, C., Tarella, C., Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells (1999) J Clin Oncol, 17, pp. 208-215 Martinelli G, Terragna C, Zamagni E, et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000;18:2.273-81Gahrton, G., Svensson, H., Bjorkstrand, B., Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation (1999) Bone Marrow Transplant, 24, pp. 741-745 Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med 1991;325:1.267-73Bensinger WI, Buckner CD, Clift RA, et al. Phase I study of busulfan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992;10:1.492-7Cavo, M., Benni, M., Cirio, T.M., Gozzetti, A., Tura, S., Allogeneic bone marrow transplantation for the treatment of multiple myeloma (1995) An overview of published reports. Stem Cells, 13 (SUPPL. 2), pp. 126-131 Bensinger, W.I., Buckner, D., Gahrton, G., Allogeneic stem cell transplantation for multiple myeloma (1997) Hematol Oncol Clin North Am, 11, pp. 147-157 Bensinger, W.I., Maloney, D., Storb, R., Allogeneic hematopoietic cell transplantation for multiple myeloma (2001) Semin Hematol, 38, pp. 243-249 Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996;88:4.711-8Arora M, McGlave PB, Burns LJ, et al. Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma. Bone Marrow Transplant 2005;35:1.133-40Bellucci R, Alyea EP, Weller E, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002;99:4.610-7Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LL, Verdonck LF. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997;90:4.206-11Alyea, E., Weller, E., Schlossman, R., T-cell - depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: Induction of graft-versus-myeloma effect (2001) Blood, 98, pp. 934-939 Collins Jr., R.H., Shpilberg, O., Drobyski, W.R., Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation (1997) J Clin Oncol, 15, pp. 433-444 Majolino, I., Corradini, P., Scime, R., High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors (2003) Bone Marrow Transplant, 31, pp. 767-773 Blade J, Vesole DH, Gertz M. High-dose therapy in multiple myeloma. Blood 2003;102:3.469-70Giralt, S., Thall, P.F., Khouri, I., Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation (2001) Blood, 97, pp. 631-637 Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allo transplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2.574-9Badros A, Barlogie B, Siegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002 20:1.295-303Lee, C.K., Badros, A., Barlogie, B., Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning (2003) Exp Hematol, 31, pp. 73-80 Barlogie, B., Shaughnessy, J., Tricot, G., Treatment of multiple myeloma (2004) Blood, 103, pp. 20-32 Giralt, S., Aleman, A., Anagnostopoulos, A., Fludarabine/ melphalan conditioning for allogeneic transplantation in patients with multiple myeloma (2002) Bone Marrow Transplant, 30, pp. 367-373 Einsele, H., Schafer, H.J., Hebart, H., Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning (2003) Br J Haematol, 121, pp. 411-418 Crawley C, Lalancette M, Szydlo R, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005;105:4.532-9Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002;100:3.919-24Maloney, D.G., Molina, A.J., Sahebi, F., Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma (2003) Blood, 102, pp. 3447-3454 Kroger, N., Schwerdtfeger, R., Kiehl, M., Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma (2002) Blood, 100, pp. 755-760 Hari, P., Pasquini, M.C., Vesole, D.H., Cure of multiple myeloma - more hype, less reality (2006) Bone Marrow Transplant, 37, pp. 1-18 Kroger N, Schilling G, Einsele H, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004;103:4.056-61Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3.474-80Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001;97:2.574-9Perez-Simon, J.A., Martino, R., Alegre, A., Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation (2003) Br J Haematol, 121, pp. 104-108 Peggs KS, Thomson K, Hart DP, et al. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood 2004;103:1.548-56Vesole DH. Transplantation for multiple myeloma: who, when, how often? Patient selection and goals. Blood 2003;102:3.471-2Smith, A., Wisloff, F., Samson, D., Guidelines on the diagnosis and management of multiple myeloma 2005 (2006) Br J Haematol, 132, pp. 410-451